甲氨蝶呤与金制剂治疗类风湿性关节炎耐受性比较的Meta分析  

Methotrexate vs.Gold Salt for Rheumatoid Arthritis:A Meta-analysis of Tolerance

作　　者：张芳[1] 陈安进[1] 付婷[1] 

机构地区：[1]青岛市市立医院,青岛市266011

出　　处：《中国药房》2008年第8期615-617,共3页China Pharmacy

摘　　要：目的:比较甲氨蝶呤与金制剂治疗类风湿性关节炎的耐受性。方法:采用Meta分析对7项甲氨蝶呤与金制剂治疗类风湿性关节炎疗效的研究进行同质性检验和合并效应量估计。结果:同质性检验:χ2=25·14,自由度为6,P=0·0003;合并效应量估计:OR合并=2·37,OR合并95%可信限为1·18～4·78。OR合并的检验Z=2·41,P=0·02。结论:与金制剂治疗类风湿性关节炎比较,甲氨蝶呤的耐受性较好。OBJECTIVE：To evaluate the efficacy of methotrexate（MTX） vs.gold salt in treating patients with rheumatoid arthritis（RA） .METHODS： 7 studies on the efficacy of methotrexate（MTX） vs.gold salt in treating patients with rheumatoid arthritis（RA） were subjected to a meta-analysis using homogeneity test and combined effect test.RESULTS： Homogeneity test showed that the cited studies were homogeneous with χ^2= 25.14, df = 6 and P = 0.0003; and by combined test, the combined OR was 2.37（95 % confidence interval = 1.18- 4.78, Z = 2.41, P = 0.02） . CONCLUSION ： Methotrexate demonstrated better toleration than gold salt for rheumatoid arthritis.

关 键 词：甲氨蝶呤 金制剂 META分析 类风湿性关节炎 

分 类 号：R969.3[医药卫生—药理学]